vida: extract claims from 2026-05-07-glp1-cns-circuit-specificity-synthesis
- Source: inbox/queue/2026-05-07-glp1-cns-circuit-specificity-synthesis.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents
parent
561b83540b
commit
efa697bfd3
4 changed files with 38 additions and 2 deletions
|
|
@ -0,0 +1,19 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: GLP-1's CNS effects track the anatomical distribution of GLP-1 receptors in VTA, nucleus accumbens, and prefrontal cortex, succeeding in reward circuit disorders (SUD, depression avolition, Parkinson's) but failing in Alzheimer's where these circuits are not primary
|
||||
confidence: experimental
|
||||
source: "Vida synthesis: EVOKE/EVOKE+ trials (Lancet March 2026), All of Us nested case-control (Frontiers Psychiatry March 2026), JAMA Psychiatry RCT (April 2026), Parkinson's meta-analysis (August 2025)"
|
||||
created: 2026-05-07
|
||||
title: GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
|
||||
agent: vida
|
||||
sourced_from: health/2026-05-07-glp1-cns-circuit-specificity-synthesis.md
|
||||
scope: causal
|
||||
sourcer: Vida synthesis
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
|
||||
related: ["medical-care-explains-only-10-20-percent-of-health-outcomes", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
|
||||
|
||||
Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pattern in GLP-1 CNS efficacy. WHERE GLP-1 WORKS: Substance use disorders show 68-75% lower odds across alcohol, opioid, nicotine, and cannabis use (All of Us observational, n>1M). Alcohol use disorder RCT demonstrated 41% reduction in heavy drinking days with NNT 4.3. Depression/anxiety/SUD worsening in pre-existing mental illness reduced 42% (Lancet Psychiatry within-individual design). MDD motivation/avolition improved in April 2026 RCT. Parkinson's motor function showed preliminary improvement across 5 Phase 2 studies. WHERE GLP-1 FAILS: Alzheimer's disease progression showed NO clinical benefit in EVOKE + EVOKE+ trials (n=3,800, Lancet March 2026) despite 10% p-tau181 biomarker reduction. No secondary endpoint improvement in any cognitive or functional domain. MECHANISTIC EXPLANATION: GLP-1 receptors concentrate in VTA, nucleus accumbens, insula, and prefrontal cortex—the reward/motivation circuits dysregulated in SUD, MDD avolition, and Parkinson's motor control (substantia nigra dopaminergic degeneration). These are NOT the circuits disrupted in Alzheimer's (medial temporal lobe, hippocampus, amyloid/tau cascade). The biomarker improvement in EVOKE likely reflects anti-inflammatory effects—real but insufficient to modify established neurodegeneration. IMPLICATION: Observational evidence showing GLP-1 users have lower dementia incidence probably reflects metabolic risk reduction (obesity, T2D → reduced vascular dementia risk) rather than direct neuroprotection. Remove the metabolic confound (EVOKE enrolled non-metabolic confirmed AD patients) and the effect disappears. This circuit specificity explains why GLP-1 crosses the clinical/non-clinical boundary specifically at the reward/behavioral interface—not generally across all CNS conditions.
|
||||
|
|
@ -143,3 +143,10 @@ Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder
|
|||
**Source:** Osmind clinical article Q1 2026
|
||||
|
||||
GLP-1 receptors in VTA suppress dopamine signaling through GABA neurons, functioning as 'a brake on the reward system.' This creates sustained dopaminergic modulation across ALL reward circuits—food, sex, social interaction, music, achievement—not just substance-related reward. The mechanism is tonic (continuous days-long activation) vs. phasic (natural 1-2 minute post-meal spikes), explaining both therapeutic benefit and anhedonia side effects.
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** Parkinson's meta-analysis (5 studies, August 2025), NeurologyLive repositioning article May 2026
|
||||
|
||||
Parkinson's motor function improvement across 5 Phase 2 studies provides additional evidence for GLP-1's dopaminergic circuit effects. Parkinson's involves substantia nigra dopaminergic degeneration—the same circuits GLP-1 modulates in SUD. This extends the dopamine modulation mechanism beyond addiction to motor control, strengthening the circuit-specificity hypothesis.
|
||||
|
|
|
|||
|
|
@ -11,7 +11,7 @@ sourced_from: health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-wor
|
|||
scope: causal
|
||||
sourcer: Lancet Psychiatry / Karolinska Institutet
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
|
||||
related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth", "social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population"]
|
||||
related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth", "social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "within-individual-design-resolves-glp1-psychiatric-confounding-by-indication"]
|
||||
---
|
||||
|
||||
# Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects
|
||||
|
|
@ -38,3 +38,10 @@ VigiBase data shows semaglutide additional psychiatric signals beyond eating dis
|
|||
**Source:** Lancet Psychiatry 2026, Karolinska Institutet
|
||||
|
||||
Within-individual design in Swedish cohort (n=95,490) confirms 44% reduction in depression worsening (HR 0.56, 95% CI 0.44-0.71) during semaglutide use periods. Design eliminates time-invariant confounding that matched cohort studies cannot address.
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** JAMA Psychiatry RCT April 2026, Vida synthesis
|
||||
|
||||
JAMA Psychiatry RCT (April 2026) showed GLP-1 improves MDD motivation/avolition specifically through effort discounting measures. This extends the depression mechanism from general 'worsening prevention' to specific improvement in motivation—a reward circuit function consistent with VTA/nucleus accumbens GLP-1R distribution.
|
||||
|
|
|
|||
|
|
@ -7,10 +7,13 @@ date: 2026-05-07
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: article
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-05-07
|
||||
priority: medium
|
||||
tags: [glp-1, CNS, neurodegeneration, Alzheimer, Parkinson, circuit-specificity, reward-circuits]
|
||||
intake_tier: research-task
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
Loading…
Reference in a new issue